Effect of weight loss on high-molecular weight adiponectin in obese children

Gabriel Á Martos-Moreno1, Vicente Barrios, Guillermo Martínez

  • 1Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, Madrid, Spain.

Insights

Weight loss in obese children improves total and high-molecular weight adiponectin levels, positively impacting carbohydrate metabolism. Sustained weight reduction is key for metabolic health improvements in pediatric obesity.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Syndrome Research
  • Adipokine Signaling

Background:

  • Childhood obesity is associated with altered adiponectin levels.
  • Understanding adiponectin's role in pediatric obesity is crucial for metabolic health.

Purpose of the Study:

  • To investigate the impact of weight reduction on total adiponectin (T-adiponectin) and high-molecular weight adiponectin (HMW-adiponectin) in obese prepubertal children.
  • To assess the relationship between adiponectin levels, body composition, and metabolic parameters following weight loss.

Main Methods:

  • Longitudinal study of 70 obese prepubertal children over 18 months with varying degrees of BMI reduction.
  • Measurement of serum adiponectin (T- and HMW-), resistin, leptin, soluble leptin receptor (sOB-R), TNF-α, and IL-6.
  • Body composition assessed by DXA; HOMA index and BMI used as metabolic indicators.

Main Results:

  • Obese children initially had higher T-adiponectin and lower HMW-adiponectin compared to controls.
  • Weight reduction increased T-adiponectin, HMW-adiponectin, and sOB-R, while decreasing leptin and IL-6.
  • HMW-adiponectin negatively correlated with HOMA index and BMI, suggesting a link to carbohydrate metabolism rather than body fat content.

Conclusions:

  • Weight loss in obese prepubertal children improves T- and HMW-adiponectin levels, correlating with improved carbohydrate metabolism.
  • The adiponectin profile in childhood obesity differs from adults, with a stronger association with metabolic parameters.
  • Weight management interventions are vital for restoring adiponectin homeostasis and metabolic health in pediatric obesity.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...